Search company, investor...

Renopharm

renopharm.com

About Renopharm

RENOPHARM Ltd uses , patent pending approach in the synthesis of Nitric Oxide (NO) donors, based on NO attachment to natural chemical groups. These chemical groups are part of physiological compounds or their natural metabolites. This compound form prevents the formation of drug tolerance induced by the current NO donor repeated treatment. The preliminary in vitro and in vivo test results demonstrate their higher effectiveness in comparison to the current medical treatment with Nitroglycerin drugs.

Headquarters Location

P.O. Box 2252

16000,

Israel

Missing: Renopharm's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Renopharm's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Renopharm Patents

Renopharm has filed 4 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/24/2008

3/13/2012

Neurological disorders, Clusters of differentiation, Proteins, Transcription factors, Tumor suppressor genes

Grant

Application Date

3/24/2008

Grant Date

3/13/2012

Title

Related Topics

Neurological disorders, Clusters of differentiation, Proteins, Transcription factors, Tumor suppressor genes

Status

Grant

Renopharm Frequently Asked Questions (FAQ)

    Discover the right solution for your team

    The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

    Request a demo

    CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.